NEW YORK (GenomeWeb News) – Atossa Genetics today said that revenues for 2012 increased sharply following the launch of two tests.

Separately, the company also said that it has entered into a $30 million stock purchase agreement with Aspire Capital.

The Seattle-based company brought in revenues of $481,842 in 2012, compared to $1,500 in 2011. Of that total $475,402 resulted from its diagnostic testing service, while $6,440 derived from sales of Atossa's MASCT Systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.